Novanta Q2 Preview: 10% Q1 Growth Sets a High Bar for Medical Tech Demand

Q1 growth makes Novanta's Q2 demand picture the real question

Q1's 10% year-over-year revenue growth made second-quarter results more important. Novanta reports after the close on August 5, and management will discuss the quarter on the conference call at 8:00 a.m. ET the next day.

The core issue is not whether Novanta can post another decent quarter. It is whether demand is becoming broader and more durable across its medical and advanced-technology customer base, and whether that demand is still converting into cash at healthy rates.

That is the main bull-bear split:

• Bulls want evidence that demand and pricing power are durable enough to support the year's framework.
• Bears do not need a macro recession call; they only need OEM capital spending to cool enough that revenue keeps growing but confidence in margins and guidance starts to weaken.

The quality of growth matters more than the headline revenue number

The first-quarter scorecard gives investors a baseline for Q2. Novanta reported GAAP revenue of $257.7 million, adjusted EBITDA of $57.1 million, and adjusted diluted EPS of $0.81. If Q2 shows similar revenue and profit progression, the business looks stable. If management also shows that growth is spreading across customers, end markets, and product lines, the quality of that growth matters more than the raw top-line move.

A stronger quarter would likely show:

• healthier bookings and order quality
• revenue growth that is not overly dependent on one large program or one cyclical market
• demand momentum across both medical and advanced-tech businesses

In Q1, Novanta reported strong bookings, growing 37% year-over-year and representing a 1.10 book-to-bill ratio. If that pattern continues, investors have a better reason to view the demand pipeline as durable rather than temporary.

Margin discipline is the other half of the test. In Q1, Adjusted EBITDA increased 14% to $57 million while revenue rose about 10%. That suggests Novanta was not simply trading off pricing to drive growth. The next check is whether that discipline holds if volumes rise.

Europe is background noise, not the main driver

The European backdrop is worth noting, but it is not the story. Recent earnings expectations for European blue-chip companies have improved, with profit growth now expected at 20.8% from a year earlier and revenue expected to rise 11.7%. But that recovery still depends heavily on energy, while healthcare remains among the weaker sectors this earnings season.

For Novanta, the more relevant signal is whether its own customers-medical device makers, life-science instrument builders, and industrial equipment manufacturers-continue spending on precision technology.

How to read the report and the call

The cleaner approach is to stay reactive rather than heroic. The quarter matters mainly if it changes the quality of the story. Novanta reports after the close of U.S. financial markets on Wednesday, August 5, 2026, so the print and the call matter more than pre-release speculation.

What would confirm the story

• Q2 revenue and EBITDA perform at least as well as Q1
• Management describes demand across multiple markets rather than one bright spot
• Bookings, backlog, and order quality still support the idea that demand is building

What would weaken it

• Revenue rises, but EBITDA clearly trails
• Demand breadth narrows or customer spending sounds softer
• Guidance language implies Q1 was a high bar rather than the start of a stronger trend

The next catalyst is the conference call on Thursday, August 6, 2026, at 8:00 a.m. ET. That is where investors should look for confirmation, not cheerleading.